These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 22280405)

  • 1. Targeting vascular changes in lesions in multiple sclerosis and experimental autoimmune encephalomyelitis.
    Karlik SJ; Roscoe WA; Patinote C; Contino-Pepin C
    Cent Nerv Syst Agents Med Chem; 2012 Mar; 12(1):7-14. PubMed ID: 22280405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. VEGF and angiogenesis in acute and chronic MOG((35-55)) peptide induced EAE.
    Roscoe WA; Welsh ME; Carter DE; Karlik SJ
    J Neuroimmunol; 2009 Apr; 209(1-2):6-15. PubMed ID: 19233483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preliminary biological evaluations of new thalidomide analogues for multiple sclerosis application.
    Contino-Pépin C; Parat A; Périno S; Lenoir C; Vidal M; Galons H; Karlik S; Pucci B
    Bioorg Med Chem Lett; 2009 Feb; 19(3):878-81. PubMed ID: 19103485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thalidomide derivatives for the treatment of neuroinflammation.
    Contino-Pépin C; Parat A; Patinote C; Roscoe WA; Karlik SJ; Pucci B
    ChemMedChem; 2010 Dec; 5(12):2057-64. PubMed ID: 20936622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bilirubin as a potent antioxidant suppresses experimental autoimmune encephalomyelitis: implications for the role of oxidative stress in the development of multiple sclerosis.
    Liu Y; Zhu B; Wang X; Luo L; Li P; Paty DW; Cynader MS
    J Neuroimmunol; 2003 Jun; 139(1-2):27-35. PubMed ID: 12799017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell-based drug delivery harnesses inflammatory and autoimmune responses in neurodegeneration.
    Pozo D
    J Mol Med (Berl); 2021 May; 99(5):673-674. PubMed ID: 33683375
    [No Abstract]   [Full Text] [Related]  

  • 7. Histamine and histamine receptors in pathogenesis and treatment of multiple sclerosis.
    Jadidi-Niaragh F; Mirshafiey A
    Neuropharmacology; 2010 Sep; 59(3):180-9. PubMed ID: 20493888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Merits and complexities of modeling multiple sclerosis in non-human primates: implications for drug discovery.
    't Hart BA; Laman JD; Kap YS
    Expert Opin Drug Discov; 2018 May; 13(5):387-397. PubMed ID: 29465302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis.
    Steinman L; Zamvil SS
    Trends Immunol; 2005 Nov; 26(11):565-71. PubMed ID: 16153891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early P2X7R-dependent activation of microglia during the asymptomatic phase of autoimmune encephalomyelitis.
    Grygorowicz T; Strużyńska L
    Inflammopharmacology; 2019 Feb; 27(1):129-137. PubMed ID: 30209761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RAM-589.555 a new Polymerase-1 inhibitor as innovative targeted-treatment for multiple sclerosis.
    Achiron A; Zilkha-Falb R; Mashiach R; Gurevich M
    J Neuroimmunol; 2017 Jan; 302():41-48. PubMed ID: 27908532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Indolin-2-ones with high in vivo efficacy in a model for multiple sclerosis.
    Bouérat L; Fensholdt J; Liang X; Havez S; Nielsen SF; Hansen JR; Bolvig S; Andersson C
    J Med Chem; 2005 Aug; 48(17):5412-4. PubMed ID: 16107139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokines in the pathogenesis and therapy of autoimmune encephalomyelitis and multiple sclerosis.
    Willenborg DO; Staykova MA
    Adv Exp Med Biol; 2003; 520():96-119. PubMed ID: 12613575
    [No Abstract]   [Full Text] [Related]  

  • 14. Immunoglobulins treatment in multiple sclerosis and experimental autoimmune encephalomyelitis.
    Achiron A; Miron S
    Mult Scler; 2000 Oct; 6 Suppl 2():S6-8; discussion S33. PubMed ID: 11188777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experimental allergic encephalomyelitis: a misleading model of multiple sclerosis.
    Sriram S; Steiner I
    Ann Neurol; 2005 Dec; 58(6):939-45. PubMed ID: 16315280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vitamin D and its immunoregulatory role in multiple sclerosis.
    Niino M
    Drugs Today (Barc); 2010 Apr; 46(4):279-90. PubMed ID: 20502725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of junctional adhesion molecule (JAM)-B ameliorates experimental autoimmune encephalomyelitis.
    Tietz S; Périnat T; Greene G; Enzmann G; Deutsch U; Adams R; Imhof B; Aurrand-Lions M; Engelhardt B
    Brain Behav Immun; 2018 Oct; 73():3-20. PubMed ID: 29920328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uric acid, a peroxynitrite scavenger, inhibits CNS inflammation, blood-CNS barrier permeability changes, and tissue damage in a mouse model of multiple sclerosis.
    Hooper DC; Scott GS; Zborek A; Mikheeva T; Kean RB; Koprowski H; Spitsin SV
    FASEB J; 2000 Apr; 14(5):691-8. PubMed ID: 10744626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tropisetron diminishes demyelination and disease severity in an animal model of multiple sclerosis.
    Aminian A; Noorbakhsh F; Ghazi-Khansari M; Kafami L; Javadi S; Hassanzadeh G; Rahimian R; Dehpour AR; Mehr SE
    Neuroscience; 2013 Sep; 248():299-306. PubMed ID: 23774631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Steroid protection in the experimental autoimmune encephalomyelitis model of multiple sclerosis.
    Garay L; Gonzalez Deniselle MC; Gierman L; Meyer M; Lima A; Roig P; De Nicola AF
    Neuroimmunomodulation; 2008; 15(1):76-83. PubMed ID: 18667803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.